Explore how political divisiveness impacts mental health and amplifies high-functioning depression, and discover strategies ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Hers breaks down the winter blues, what causes them, and research-backed tips for handling this seasonal mood change.

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...

Have you been feeling down this winter? You’re not alone.Clinical Counselor Adam Kleinman said that the cold weather and gray ...

A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...